Biosimilar DTC Outlook—Is 2020 the Year of Opportunity?
![Evoke](/wp-content/uploads/2019/04/evoke-logo-white.png)
29 January 2020
Evoke
“With momentum in Washington and increased advocacy from patients and payers, this could be the year of opportunity biosimilar manufacturers have been waiting for.” – Jeff Greene, VP, Strategy
View the full article here
Back to News